Search

Your search keyword '"Lee, Kuei-Chuan"' showing total 384 results
Start Over Author "Lee, Kuei-Chuan"
384 results on '"Lee, Kuei-Chuan"'

1. Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation

Author

Kim, Dong-Sik, Yoon, Young-In, Kim, Beom Kyung, Choudhury, Ashok, Kulkarni, Anand, Park, Jun Yong, Kim, Jongman, Sinn, Dong Hyun, Joo, Dong Jin, Choi, YoungRok, Lee, Jeong-Hoon, Choi, Ho Joong, Yoon, Ki Tae, Yim, Sun Young, Park, Cheon-Soo, Kim, Deok-Gie, Lee, Hae Won, Choi, Won-Mook, Chon, Young Eun, Kang, Woo-Hyoung, Rhu, Jinsoo, Lee, Jae Geun, Cho, Yuri, Sung, Pil Soo, Lee, Han Ah, Kim, Ji Hoon, Bae, Si Hyun, Yang, Jin Mo, Suh, Kyung-Suk, Al Mahtab, Mamun, Tan, Soek Siam, Abbas, Zaigham, Shresta, Ananta, Alam, Shahinul, Arora, Anil, Kumar, Ashish, Rathi, Pravin, Bhavani, Ruveena, Panackel, Charles, Lee, Kuei Chuan, Li, Jun, Yu, Ming-Lung, George, Jacob, Tanwandee, Tawesak, Hsieh, Sen-Yung, Yong, Chee Chien, Rela, Mohamed, Lin, H. C., Omata, Masao, and Sarin, Shiv Kumar

Published
2024
Full Text
View/download PDF

4. Acetate reprograms gut microbiota during alcohol consumption

Author

Martino, Cameron, Zaramela, Livia S, Gao, Bei, Embree, Mallory, Tarasova, Janna, Parker, Seth J, Wang, Yanhan, Chu, Huikuan, Chen, Peng, Lee, Kuei-Chuan, Galzerani, Daniela Domingos, Gengatharan, Jivani M, Lekbua, Asama, Neal, Maxwell, Knight, Rob, Tsukamoto, Hidekazu, Metallo, Christian M, Schnabl, Bernd, and Zengler, Karsten

Subjects
Chronic Liver Disease and Cirrhosis, Substance Misuse, Alcoholism, Alcohol Use and Health, Nutrition, Liver Disease, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Oral and gastrointestinal, Good Health and Well Being, Acetates, Alcohol Drinking, Animals, Ethanol, Gastrointestinal Microbiome, Liver Diseases, Mice, Mice, Inbred C57BL
Abstract

Liver damage due to chronic alcohol use is among the most prevalent liver diseases. Alcohol consumption frequency is a strong factor of microbiota variance. Here we use isotope labeled [1-13C] ethanol, metagenomics, and metatranscriptomics in ethanol-feeding and intragastric mouse models to investigate the metabolic impacts of alcohol consumption on the gut microbiota. First, we show that although stable isotope labeled [1-13C] ethanol contributes to fatty acid pools in the liver, plasma, and cecum contents of mice, there is no evidence of ethanol metabolism by gut microbiota ex vivo under anaerobic conditions. Next, we observe through metatranscriptomics that the gut microbiota responds to ethanol-feeding by activating acetate dissimilation, not by metabolizing ethanol directly. We demonstrate that blood acetate concentrations are elevated during ethanol consumption. Finally, by increasing systemic acetate levels with glyceryl triacetate supplementation, we do not observe any impact on liver disease, but do induce similar gut microbiota alterations as chronic ethanol-feeding in mice. Our results show that ethanol is not directly metabolized by the gut microbiota, and changes in the gut microbiota linked to ethanol are a side effect of elevated acetate levels. De-trending for these acetate effects may be critical for understanding gut microbiota changes that cause alcohol-related liver disease.

Published
2022

8. Fecal Carriage of Multidrug-Resistant Organisms Increases the Risk of Hepatic Encephalopathy in Cirrhotic Patients: Insights from Gut Microbiota and Metabolite Features

Author

Wu, Peishan, primary, Lee, Pei-Chang, additional, Chang, Tien-En, additional, Hsieh, Yun-Cheng, additional, Chiou, Jen-Jie, additional, Lin, Chao-Hsiung, additional, Huang, Yi-Long, additional, Lin, Yi-Tsung, additional, Huo, Teh-Ia, additional, Schnabl, Bernd, additional, Lee, Kuei-Chuan, additional, and Hou, Ming-Chih, additional

Published
2024
Full Text
View/download PDF

16. Mac-2-Binding Protein Glycosylation Isomer to Albumin Ratio Predicts Bacterial Infections in Cirrhotic Patients.

Author

Wu, Pei-Shan, Hsieh, Yun-Cheng, Lee, Pei-Chang, Yang, Tsung-Chieh, Chen, Yu-Jen, Yang, Ying-Ying, Huang, Hui-Chun, Hsu, Shao-Jung, Huo, Teh-Ia, Lee, Kuei-Chuan, Lin, Han-Chieh, and Hou, Ming-Chih

Subjects
BACTERIAL diseases, ISOMERS, RECEIVER operating characteristic curves, HEPATIC fibrosis, PROPORTIONAL hazards models
Abstract

Introduction: Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel biomarker for liver fibrosis, but little is known about its role in cirrhosis-associated clinical outcomes. This study aimed to investigate the predictive role of M2BPGi in cirrhosis-associated complications. Methods: One hundred and forty-nine cirrhotic patients were retrospectively enrolled. Patients were followed up for 1 year, and cirrhosis-associated clinical events were recorded. Receiver operating characteristic curve (ROC) analysis was used to establish the values of the predictive models for cirrhotic outcomes, and Cox proportional hazards regression models were used to identify predictors of clinical outcomes. Results: Sixty (40.3%) patients experienced cirrhosis-associated clinical events and had higher M2BPGi levels compared to those without events (8.7 vs. 5.1 cutoff index, p < 0.001). The most common cirrhosis-associated complications were bacterial infections (24.2%). On ROC analysis, M2BPGi to albumin ratio (M2BPGi/albumin) had comparable discriminant abilities for all cirrhosis-associated events (area under the ROC curve [AUC] = 0.74) compared with M2BPGi, Child-Pugh, model for end-stage liver disease, albumin-bilirubin scores, and neutrophil-to-lymphocyte ratio and was superior to M2BPGi alone for all bacterial infectious events (AUC = 0.80). Cox regression analysis revealed that the M2BPGi/albumin, but not M2BPGi alone, independently predicted all cirrhosis-associated events (hazard ratio [HR] = 1.34, p = 0.038) and all bacterial infectious events (HR = 1.51, p = 0.011) within 1 year. However, M2BPGi/albumin did not predict other cirrhotic complications and transplant-free survival. Discussion/Conclusion: M2BPGi/albumin might serve as a potential prognostic indicator for patients with cirrhosis, particularly for predicting bacterial infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis

Author

Lee, Pei-Chang, primary, Lee, Kuei-Chuan, additional, Lu, Hsiao-Sheng, additional, Chen, Yu-Jen, additional, Cheng, Tsung-Yi, additional, Yang, Tsung-Chieh, additional, Chiou, Jen-Jie, additional, Huang, Chi-Wei, additional, Yang, Ueng-Cheng, additional, Huang, Yi-Hsiang, additional, and Hou, Ming-Chih, additional

Published
2023
Full Text
View/download PDF

22. Assuring safety of fecal microbiota transplantation in the COVID‐19 era: A single‐center experience.

Author

Chang, Tien‐En, Lee, Kuei‐Chuan, Lee, Pei‐Chang, Wang, Yen‐Po, Lin, Yi‐Tsung, Huang, Hui‐Chun, Luo, Jiing‐Chyuan, Ho, Hsiang‐Ling, Huang, Yi‐Hsiang, and Hou, Ming‐Chih

Subjects
SARS-CoV-2, COVID-19 pandemic, FECAL microbiota transplantation, NUCLEIC acid amplification techniques, MULTIDRUG resistance
Abstract

Background and Aim: Fecal microbiota transplantation (FMT) is used to treat recurrent or refractory Clostridioides difficile infection (CDI). In the past, screening of fecal donors required surveillance of personal behavior, medical history, and diseases that could be transmitted by the blood or fecal–oral route. In addition, the exclusion of multidrug‐resistant organisms (MDROs) has been recommended since 2018. This task has become more complicated in the era of the coronavirus disease‐2019 (COVID‐19) pandemic. To prevent fecal transmission of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), it is crucial to commence screening for SARS‐CoV‐2, alongside other traditional tests. Our aim was to investigate whether hidden carriers of SARS‐CoV‐2 were enrolled for stool donation, and the status of the presence or incidence of MDRO during fecal donation in Taiwan. Methods: Fecal products collected from March 2019 to December 2022 were tested for MDRO and nucleic acid amplification tests for SARS‐CoV‐2 using the pooling method. The period of fecal product collection crossed the time before and during the COVID pandemic in Taiwan. Results: A total of 151 fecal samples were collected. The fecal products were tested using polymerase chain reaction (PCR) to detect SARS‐CoV‐2. The results were negative for all stocks. This was similar to the results of MDRO testing. The safety of FMT products has been guaranteed during the pandemic. Conclusion: Our FMT center produced MDRO‐free and COVID‐19‐free products before and during the COVID‐19 outbreak in Taiwan. Our protocol was effective for ensuring the safety of FMT products. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Serum adrenomedullin and urinary thromboxane B2 help early categorizing of acute kidney injury in decompensated cirrhotic patients: A prospective cohort study

Author

Liu, Chih‐Wei, Huang, Chia‐Chang, Tsai, Hung‐Cheng, Su, Yen‐Bo, Huang, Shiang‐Fen, Lee, Kuei‐Chuan, Hsieh, Yun‐Cheng, Li, Tzu‐Hao, Tsai, Chang‐Youh, Chong, Lee‐Won, Ou, Shuo‐Ming, Yang, Ying‐Ying, Fan, Wen‐Chien, Hou, Ming‐Chih, Lin, Han‐Chieh, and Lee, Shou‐Dong

Published
2018
Full Text
View/download PDF

50. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response

Author

Hsieh, Yun-Cheng, primary, Lee, Kuei-Chuan, additional, Su, Chien-Wei, additional, Lan, Ken-Hsin, additional, Huo, Teh-Ia, additional, Wang, Yuan-Jen, additional, Huang, Hui-Chun, additional, Lin, Han-Chieh, additional, Chu, Chi-Jen, additional, Huang, Yi-Hsiang, additional, and Hou, Ming-Chih, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results